Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.33 - $10.44 $314,160 - $9.94 Million
-952,002 Reduced 4.77%
19,022,656 $7.61 Million
Q1 2022

May 16, 2022

BUY
$1.06 - $2.1 $3.09 Million - $6.12 Million
2,912,500 Added 17.07%
19,974,658 $28.2 Million
Q4 2021

Feb 14, 2022

BUY
$2.05 - $3.2 $4.27 Million - $6.67 Million
2,084,900 Added 13.92%
17,062,158 $35 Million
Q3 2021

Nov 15, 2021

BUY
$2.54 - $4.07 $9.38 Million - $15 Million
3,691,000 Added 32.7%
14,977,258 $46.1 Million
Q2 2021

Aug 16, 2021

SELL
$2.57 - $4.85 $500,471 - $944,469
-194,736 Reduced 1.7%
11,286,258 $45.9 Million
Q1 2021

May 17, 2021

BUY
$1.9 - $2.82 $570,000 - $846,000
300,000 Added 2.68%
11,480,994 $28.4 Million
Q4 2020

Feb 12, 2021

BUY
$1.15 - $2.4 $497,949 - $1.04 Million
433,000 Added 4.03%
11,180,994 $23.8 Million
Q3 2020

Nov 13, 2020

BUY
$1.11 - $1.68 $6.35 Million - $9.61 Million
5,719,000 Added 113.72%
10,747,994 $13 Million
Q2 2020

Aug 14, 2020

SELL
$1.69 - $4.2 $2.2 Million - $5.46 Million
-1,300,000 Reduced 20.54%
5,028,994 $8.65 Million
Q2 2019

Aug 14, 2019

BUY
$1.25 - $3.14 $3.52 Million - $8.84 Million
2,815,000 Added 80.11%
6,328,994 $9.56 Million
Q4 2018

Feb 14, 2019

BUY
$3.23 - $7.01 $4.93 Million - $10.7 Million
1,527,000 Added 76.85%
3,513,994 $11.8 Million
Q3 2018

Nov 14, 2018

SELL
$6.86 - $9.97 $1.75 Million - $2.55 Million
-255,359 Reduced 11.39%
1,986,994 $14.4 Million
Q2 2018

Aug 14, 2018

SELL
$2.88 - $8.67 $1.42 Million - $4.29 Million
-494,647 Reduced 18.07%
2,242,353 $15.4 Million
Q1 2018

May 07, 2018

BUY
$2.92 - $3.81 $1.42 Million - $1.86 Million
487,000 Added 21.64%
2,737,000 $8.16 Million
Q4 2017

Feb 14, 2018

BUY
$2.99 - $4.85 $6.73 Million - $10.9 Million
2,250,000
2,250,000 $6.91 Million

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.